bioRxivBiochemistryPreprint
TMPRSS6 Cleavage of β-Klotho Modulates FGF19 Signaling
Matthieu LepageiD, Antoine DésiletsiD, Gabriel LemieuxiD, Michael DesgagnéiD, Pierre‐Luc BoudreaultiD, Richard LeduciD
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent liver disorder worldwide, yet therapeutic options remain limited. TMPRSS6, a liver serine protease best known for its role in iron homeostasis, has recently emerged as a potential therapeutic target for MASLD. However, the molecular mechanisms linking TMPRSS6 to hepatic lipid metabolism remain incompletely understood. To identify novel TMPRSS6 substrates, we performed extracellular proteomic analyses of TMPRSS6-overexpressing cells. Among the proteins identified, {beta}-klotho (KLB), a co-receptor required for FGF19 and FGF21 signaling, emerged as a compelling candidate substrate. We demonstrate that TMPRSS6 interacts with KLB and promotes its proteolytic shedding in a catalytic activity-dependent manner. Functionally, TMPRSS6 reduced full-length KLB abundance at the cell surface and attenuated FGF19-dependent FGFR4 signaling in a heterologous expression system. Together, these findings identify KLB as a novel functional substrate of TMPRSS6, providing a mechanistic framework through which this protease may influence hepatic lipid metabolism. These results provide a rationale for investigating the regulation of KLB and other candidate substrates by TMPRSS6 in physiological models and further support its evaluation as a therapeutic target for MASLD.
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The MASLD-causing E167K variant of TM6SF2 is degraded by the ubiquitin ligase RNF5
Emad Heidary Arash, Huimin Pan, Holger Willenbring·bioRxiv·Oct 23, 2026
- MTARC1 Regulates Lipid Droplet Degradation via Phospholipid Remodeling in Metabolic Fatty Liver Disease
- The Lipid Hydrolase ABHD6 is a Therapeutic Target in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Related Hepatocellular Carcinoma
Danny Orabi, William J. Massey, … J. Mark Brown·bioRxiv·Jul 29, 2025
- TLR4 promotes liver fibrosis in metabolic dysfunction-associated steatohepatitis by a mechanism independent of hepatocytes and inflammatory cells
Eliza Elza Altvater, Daniah Kojh, … Jorge Matías Caviglia·bioRxiv·Sep 25, 2025
- Hepatocyte-specific CLSTN3B ablation impairs lipid droplet maturation and alleviates diet-induced steatohepatitis in mice
Chuanhai Zhang, Dengbao Yang, … Xing Zeng·bioRxiv·May 20, 2025
- Protein tyrosine phosphatase receptor kappa regulates glycolysis and de novo lipogenesis to promote hepatocyte metabolic reprogramming in obesity
E. H. Gilglioni, A. Li, … E. N. Gurzov·bioRxiv·Dec 1, 2023